Study to Assess the Efficacy of Medi-Tate iTind Device

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will include an implantation of the iTind device and 4 follow up visits up to 12 months after the implantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pivotal Study to Assess the Safety and Effectiveness of the iTind Device

NCT02506465

Benign Prostate Hyperplasia

COMPLETED NA

Study to Assess the Efficacy, Safety and Tolerability of (iTind)

NCT03239951

BPH

TERMINATED NA

Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia

NCT01436877

Bladder Neck Obstruction Benign Prostate Hyperplasia

COMPLETED NA

Post-Market Study to Assess iTind Safety in Comparison to UroLift

NCT04757116

Benign Prostatic Hyperplasia (BPH)

RECRUITING NA

Implanted Nitinol Device (iTind) System in Chinese Males With Lower Urinary Tract Symptom Secondary to BPH

NCT05440981

Prostate Hyperplasia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After screening , eligible patients will undergo an an implantation procedure (operative), using the iTind device.

Implantation will be performed according to the Instructions For Use.

Between the 5th - 7th days, the iTind will be retrieved through a rigid cystoscope sheath, under direct vision. Before retrieval the subject will be asked for subjective discomfort evaluation and level of urgency in the past days after device insertion, about any AE and then the device will be retrieved.

The next visits will be at 4 weeks (post device retrieval), 3 months, 6 months, and 12 months post implantation with an optional extension of follow up period (up to 36 months). In the visits the following will be assessed: Uroflow and residual urine volume tests, AE recording, IPSS, and Questions on sex performing capability and ejaculation filled out by the subjects, in the local languages.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Prostatic Hyperplasia (BPH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

iTind

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Medi-Tate iTind

TIND System

Group Type EXPERIMENTAL

TIND System

Intervention Type DEVICE

An implant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TIND System

An implant

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject signed informed consent prior to the performance of any study procedures.
* Male with symptomatic BPH. IPSS symptom severity score above 10. Peak urinary flow of below 12 ml/sec
* Prostate volume below 75 ml
* Blood CBC and biochemistry up to two weeks before screening demonstrating: Normal values of the PT, PTT and INR tests (anticoagulants should be stopped according to GCP)
* Subject that able to complete the study protocol.
* Normal Urinalysis and urine culture

Exclusion Criteria

* cardiac arrhythmias, cardiac disease including congestive heart failure, uncontrolled diabetes mellitus, significant respiratory disease, or known immunosuppression;
* neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes, etc.;
* a post void residual (PVR) volume above 250 ml measured by ultrasound or acute urinary retention
* compromised renal function (i.e., serum creatinine level above 1.8 mg/dl, or upper tract disease);
* confirmed or suspected bladder cancer;
* recent (within 3 months) cystolithiasis or hematuria;
* urethral strictures, bladder neck contracture, Urinary bladder stones
* or other potentially confounding bladder pathology;
* an active urinary tract infection.
* Enrolled in another treatment trial for any disease within the past 30 days.
* previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used;
* previous pelvic irradiation or radical pelvic surgery;
* previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate
* Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years).
* Subject has an interest in future fertility and is not willing to undergo fertility treatments whatsoever.
* Any serious medical condition likely to impede successful completion of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No